Lengo blueprint12/17/2023 ![]() ![]() Lengo’s Chief Executive, Enoch Kariuki, is the former chief financial officer of Velos. It has ties to VelosBio, a local oncology biotech that was acquired last year by Merck for $2.75 billion. The company employs 11 full-time workers. ![]() But it’s at least $17.7 million, according to filings with the U.S. The company declined to disclose how much it raised. ![]() Lengo was founded in 2019 by venture capital firm Frazier Healthcare Partners. It also has other precision oncology programs for non-small-cell lung cancer in early development. The company could receive up to $215 million in additional payments based on regulatory approvals and sales targets. Food and Drug Administration by the end of this year, a precursor to clinical trials. Lengo is on track to submit an Investigational New Drug Application for LNG-451 to the U.S. “With the addition of LNG-451 to our pipeline, we will have three investigational therapies, each of which has best-in-class potential.” The acquisition “complements our existing portfolio and strengthens our position in lung cancer,” said Blueprint Chief Executive Jeffrey Albers in a conference call with investors. Lengo’s molecule aims to enable treatment or prevention of brain metastases, which are a particular risk for patients with non-small-cell lung cancer. Lengo, which is located in Carmel Valley, is working on a novel medicine - called LNG-451 - that targets mutations that drive the spread of certain types of cancer to other parts of the body. based company has one approved drug, Gavreto, and two others in clinical trials. 29, aims to fill a niche in Blueprint’s portfolio of lung cancer therapies. San Diego oncology startup Lengo Therapeutics is being acquired by publicly traded Blueprint Medicines for $250 million in cash - and possibly more if it hits certain milestones - to push forward an experimental precision treatment for patients with non-small-cell lung cancer. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |